Gilead Sciences Inc - GILD STOCK NEWS

Gilead Sciences has announced that the Mary Bird Perkins Cancer Center, a grantee of Gilead, is expanding its mobile cancer screening services in Louisiana and Mississippi. This initiative aims to increase access to early cancer detection, particularly in communities with higher mortality rates from advanced cancer diagnoses. The mobile clinics, operational since 2006, now serve 30 parishes in Louisiana and four counties in Mississippi, offering screenings for various cancers, including breast and prostate. The project is part of Gilead's Toward Health Equity Oncology Grant, which supports interventions for Black individuals impacted by breast cancer.

Gilead Sciences (NASDAQ: GILD) announced promising results from the Phase 2 TROPHY-U-01 trial of Trodelvy (sacituzumab govitecan-hziy) for metastatic urothelial cancer (mUC). Key findings include:

• 13.5 months median overall survival (OS) in platinum-ineligible patients.
• 12.8 months OS in rapidly progressing mUC post-platinum therapy.
• 10.9 months OS for patients after platinum-based chemotherapy and checkpoint inhibitors.

These results indicate potential for Trodelvy as a cornerstone treatment for challenging mUC cases. Gilead anticipates further data from the ongoing Phase 3 TROPiCS-04 study.

Gilead Sciences is committed to innovation, with plans to deliver over 10 transformative therapies by 2030 across virology, oncology, and inflammation. Recent strategic moves include the acquisition of MiroBio, which focuses on restoring immune balance, and a partnership with MacroGenics to develop bispecific antibodies for blood cancers. A new Research Center is set to be established in Foster City, featuring 175,000 square feet of lab space to enhance research capabilities. This facility aligns with Gilead's sustainable practices and is designed to foster collaboration among researchers.

Gilead Sciences (GILD) announced new clinical and real-world data presentations at the 30th Conference on Retroviruses and Opportunistic Infections (CROI) from February 19-22. Featuring 70 abstracts, the data encompasses HIV, COVID-19, and viral hepatitis research. Key highlights include Phase 1b data on lenacapavir for HIV treatment, real-world effectiveness of Veklury (remdesivir) for COVID-19, and ongoing trials evaluating Biktarvy in HIV/HBV co-infection. Gilead emphasizes its commitment to innovative solutions for pressing health needs, aiming to improve treatment outcomes and patient care globally. The new findings underscore Gilead's leadership in virology research.

Kite, a Gilead Company (Nasdaq: GILD), announced three-year follow-up results from the ZUMA-3 study on Tecartus, a CAR T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). The study reported a median overall survival of 26 months, with a durable response rate of 71% in adults. Notable findings included an overall complete remission (CR) rate of 56% and a sustained median relapse-free survival of around 11.6 months. Investigators emphasized the potential for Tecartus to establish a new standard of care for this aggressive leukemia, encouraging ongoing research and treatment advancements.

Gilead Sciences focuses on innovative therapies for breast cancer, particularly metastatic HR+/HER2- types, accounting for about 70% of all breast cancer diagnoses globally. The company is advancing a development program to address critical gaps in treatment, including the use of antibody-drug conjugates (ADCs) that target tumor cells. As of 2023, Gilead is running over 50 active or planned cancer clinical trials and aims to gain 10 new indications by 2026. The survival rate for metastatic HR+/HER2- breast cancer is notably low, highlighting the urgency for new treatment options that enhance quality of life while minimizing chemotherapy's side effects.

Gilead Sciences announced FDA approval for Trodelvy (sacituzumab govitecan-hziy) to treat hormone receptor-positive, HER2-negative metastatic breast cancer in patients who have undergone endocrine therapy and at least two chemotherapies. The approval stems from the Phase 3 TROPiCS-02 study, indicating an overall survival benefit of 3.2 months compared to chemotherapy. Trodelvy is now a preferred treatment option as per the NCCN guidelines. The safety profile aligns with previous studies, showing common side effects such as diarrhea and neutropenia, while also maintaining its market potential with ongoing regulatory reviews in over 40 countries.

Gilead Sciences, Inc. (NASDAQ: GILD) has declared a 2.7% increase in its quarterly cash dividend, now set at $0.75 per share. This increase will begin in the first quarter of 2023, with dividends payable on March 30, 2023 to stockholders on record by March 15, 2023. Future dividends are contingent on Board approval. Gilead continues to focus on innovative medicines for serious diseases, including HIV and cancer, operating in over 35 countries globally.

Gilead Sciences (Nasdaq: GILD) reported its fourth quarter and full year 2022 financial results, highlighting an overall revenue increase of 2% to $7.4 billion in Q4. Notable year-over-year sales growth included Oncology sales up 71%, and Biktarvy sales rising 20% to $10.4 billion for the year. However, Veklury sales fell 26% in Q4 and decreased 30% for the year, reflecting reduced COVID-19 hospitalizations. Diluted EPS for Q4 was $1.30, a significant increase from $0.30 in 2021. For 2023, Gilead anticipates total product sales between $26.0 billion and $26.5 billion, with a focus on continued growth in HIV and oncology products.